Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (291-300 of 635) with videos related to

Pageof 64
Sort By:
Thrombosis and Haemostasis|April 7, 2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX studyWilliam A Parker, Deepak L Bhatt, Jayne Prats, et al.
European Heart Journal|August 30, 2011
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentKeith A A Fox, Jonathan P Piccini, Daniel Wojdyla, et al.
Journal of the American Heart Association|May 27, 2022
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery DiseaseMichael Szarek, Connie Hess, Manesh R Patel, et al.
Journal of Cardiac Failure|April 28, 2023
Clinical and Echocardiographic Diversity Associated With Physical Fitness in the Project Baseline Health Study: Implications for Heart Failure StagingNicholas Cauwenberghs, Francois Haddad, Melissa A Daubert, et al.
Vascular Medicine (London, England)|September 13, 2021
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trialLars Norgren, Rebecca North, Iris Baumgartner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 20, 2024
Canagliflozin and iron metabolism in the CREDENCE trialAkihiko Koshino, Hiddo J L Heerspink, Niels Jongs, et al.
The American Journal of Medicine|April 12, 2017
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and WhitesMasaya Koshizaka, Renato D Lopes, L Kristin Newby, et al.
American Heart Journal|February 9, 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network TrialKenneth W Mahaffey, Matthew T Roe, Christopher K Dyke, et al.
Circulation|January 15, 2016
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) TrialMichelle L O'Donoghue, Deepak L Bhatt, Gregg W Stone, et al.
Circulation|August 3, 2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Pageof 64

Showing results (291-300 of 635) with videos related to

Sort By:
Pageof 64
Thrombosis and Haemostasis|April 7, 2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX studyWilliam A Parker, Deepak L Bhatt, Jayne Prats, et al.
European Heart Journal|August 30, 2011
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentKeith A A Fox, Jonathan P Piccini, Daniel Wojdyla, et al.
Journal of the American Heart Association|May 27, 2022
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery DiseaseMichael Szarek, Connie Hess, Manesh R Patel, et al.
Journal of Cardiac Failure|April 28, 2023
Clinical and Echocardiographic Diversity Associated With Physical Fitness in the Project Baseline Health Study: Implications for Heart Failure StagingNicholas Cauwenberghs, Francois Haddad, Melissa A Daubert, et al.
Vascular Medicine (London, England)|September 13, 2021
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trialLars Norgren, Rebecca North, Iris Baumgartner, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 20, 2024
Canagliflozin and iron metabolism in the CREDENCE trialAkihiko Koshino, Hiddo J L Heerspink, Niels Jongs, et al.
The American Journal of Medicine|April 12, 2017
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and WhitesMasaya Koshizaka, Renato D Lopes, L Kristin Newby, et al.
American Heart Journal|February 9, 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network TrialKenneth W Mahaffey, Matthew T Roe, Christopher K Dyke, et al.
Circulation|January 15, 2016
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) TrialMichelle L O'Donoghue, Deepak L Bhatt, Gregg W Stone, et al.
Circulation|August 3, 2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Pageof 64